# US 2013/0252913 A1 · 18-Membered Macrocycles and Analogs Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0252913 A1
- Document ID: US20130252913A1
- Status: Published application
- Kind: A1
- Application number: 13/838,634
- Filed: 2013-03-15
- Published: 2013-09-26
- Earliest claimed: 2005-01-31
- Assignees: Optimer Pharmaceuticals, Inc.
- Applicants: Optimer Pharmaceuticals, Inc.
- Inventors: Youe-Kong Shue; Chan-Kou Hwang; Yu-Hung Chiu; Alex Romero; Farah Babakhani; Pamela Sears; Franklin Okumu
- Web page: https://patentgrep.com/patent/US20130252913A1

## CPC

- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61P 1/12: Antidiarrhoeals
- A61P 31/04: Antibacterial agents
- C07H 17/08: Hetero rings containing eight or more ring members, e.g. erythromycins
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)

## Abstract

The present invention relates generally to the 18-membered macrocyclic antimicrobial agents called Tiacumicins, specifically, OPT-80 (which is composed almost entirely of the R-Tiacumicin B), pharmaceutical compositions comprising OPT-80, and methods using OPT-80. In particular, this compound is a potent drug for the treatment of bacterial infections, specifically C. difficile infections.

## Claims

### Claim 1

A substantially stereomerically pure compound having the formula:
or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

### Claim 2 (depends on 1)

The compound of claim 1, which is greater than 90% stereomeric purity.

### Claim 3 (depends on 1)

The compound of claim 1, which is greater than 95% stereomeric purity.

### Claim 4 (depends on 1)

The compound of claim 1, which is greater than 99% stereomeric purity.

### Claim 5

A composition comprising a substantially stereomerically pure compound having the formula:
or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

### Claim 6 (depends on 5)

The composition of claim 5, wherein the compound is greater than 90% stereomeric purity.

### Claim 7 (depends on 5)

The composition of claim 5, wherein the compound is greater than 95% stereomeric purity.

### Claim 8 (depends on 5)

The composition of claim 5, wherein the compound is greater than 99% stereomeric purity.

### Claim 9 (depends on 5)

The composition of claim 5 further comprising a pharmaceutically acceptable carrier.

### Claim 10 (depends on 5)

The composition of claim 5 further comprising 0-20% of Tiacumicin B related compounds.

### Claim 11 (depends on 10)

The composition of claim 10, wherein said Tiacumicin B related compounds is selected from the group consisting of Lipiarmycin A4 and C-19 Ketone.

### Claim 12 (depends on 5)

The composition of claim 5 further comprised of an additional agent selected from the group consisting of an antimicrobial agent and an antifungal agent.

### Claim 13 (depends on 5)

The composition of claim 5 suitable for oral administration.

### Claim 14 (depends on 5)

The composition of claim 5 suitable for parenteral administration.

### Claim 15 (depends on 5)

The composition of claim 5, wherein the compound is present in an amount of about 0.015-0.25 μg/mL.

### Claim 16 (depends on 5)

A method for treating bacterial infections in a mammal, which comprises administering to said mammal a composition comprising a therapeutically effective amount of said composition of claim 5.
